Circovirus

• 15 minutes

Grants amounting to €650,000 have been awarded to European projects since 2007 under an annual programme to encourage applied research into the circovirus PCV2 and the disease pictures linked to it.  Decisions on pig health care have changed significantly in Europe over the past decade, regarding the use of vaccination in controlling the diseases associated with the virus known as PCV2. It is an extraordinary story of success that continues to expand as applied research and practical experience give even better insights into the virus itself and the diseases associated with it.

• 10 minutes

For the ninth time, Boehringer Ingelheim Animal Health has funded independent European research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Over the past nine years, 26 research projects have been awarded with € 25,000 each accumulating to € 650,000 in total.

• 10 minutes

US - In the latest 'At the Meeting' (ATM) audio program on swine health from the Morrison Group, leading swine veterinarians take on the historic and novel work regarding porcine circovirus (PCV2), including prevention, new diagnostic methods and vertical transmission’s impact on pig production and sow herds.

• 5 minutes

Boehringer Ingelheim Animal Health has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/ Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU) vaccine combination. As a consequence of this decision, the company has discontinued its PCV2/M.hyo RTU research program.